GlassScriptPhysician profile
Tannaz Armaghany
NPI 1144358516
$14,274.51
in general payments reported to CMS, 2019-2025
21 companies · $4,950 in 2025
The $4,950 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,713 · 2020: $129 · 2021: $35.70 · 2022: $744 · 2023: $2,563 · 2024: $140 · 2025: $4,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,750 · Consulting Fee: $2,280 · Travel and Lodging: $1,755 · Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,750.00 |
| Consulting Fee | $2,280.00 |
| Travel and Lodging | $1,755.08 |
| Food and Beverage | $868.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $5,389.84 | 2019 | |
| Exelixis INC. | $4,692.57 | 2025 | Cabometyx |
| Eisai INC. | $2,461.26 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $656.44 | 2019-2025 | Onivyde |
| Boston Scientific Corporation | $186.50 | 2022 | |
| Janssen Biotech, INC. | $182.46 | 2022 | |
| Aveo Pharmaceuticals, INC. | $144.32 | 2021-2023 | Fotivda |
| Novartis Pharmaceuticals Corporation | $94.24 | 2022 | |
| Amgen INC. | $78.97 | 2019-2022 | |
| Abbvie INC. | $74.01 | 2019-2022 | |
| Nevro Corp. | $70.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $55.43 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $42.42 | 2023 | Epkinly, Imbruvica |
| Regeneron Healthcare Solutions, INC. | $36.64 | 2022 | |
| Lilly USA, LLC | $32.26 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.40 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.45 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 | |
| Clovis Oncology, INC. | $10.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tannaz Armaghany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.